Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model

Drug‐induced prolongation of the QT interval can lead to torsade de pointes, a life‐threatening ventricular arrhythmia. Finding appropriate assays from among the plethora of options available to predict reliably this serious adverse effect in humans remains a challenging issue for the discovery and development of drugs. The purpose of the present study was to develop and verify a reliable and relatively simple approach for assessing, during preclinical development, the propensity of drugs to prolong the QT interval in humans.

[1]  J. Shimada,et al.  Clinical Pharmacokinetics of Sparfloxacin , 1993, Clinical pharmacokinetics.

[2]  C. White,et al.  Clinical Pharmacokinetics and Selective Pharmacodynamics of New Angiotensin Converting Enzyme Inhibitors , 2002, Clinical pharmacokinetics.

[3]  Daniela S Hauser,et al.  Cardiovascular parameters in anaesthetized guinea pigs: a safety pharmacology screening model. , 2005, Journal of pharmacological and toxicological methods.

[4]  I. Cavero.  Safety Pharmacology Society: 7th annual meeting 19 - 20 September 2007, Edinburgh, UK. , 2008, Expert opinion on drug safety.

[5]  Cavero,et al.  QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. , 1999, Pharmaceutical science & technology today.

[6]  R. Woestenborghs,et al.  Excretion and biotransformation of cisapride in dogs and humans after oral administration. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[7]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[8]  M. Rosen,et al.  Chronic in vivo and in vitro effects of amiodarone on guinea pig hearts. , 1996, The Journal of pharmacology and experimental therapeutics.

[9]  B. Darpö,et al.  Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes , 2001 .

[10]  A. Brown,et al.  Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. , 2004, Journal of pharmacological and toxicological methods.

[11]  P. Kowey,et al.  Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. , 2006, Heart rhythm.

[12]  A. Hoes,et al.  Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. , 2005, European heart journal.

[13]  J. Gras,et al.  Effects of H1 Antihistamines on Animal Models of QTc Prolongation , 1999, Drug safety.

[14]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[15]  R. Anziano,et al.  The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. , 2000, British journal of clinical pharmacology.

[16]  Y. Mizuki,et al.  Effects of 5-HT4 receptor agonists, cisapride and mosapride citrate on electrocardiogram in anaesthetized rats and guinea-pigs and conscious cats , 2001 .

[17]  C. Antzelevitch.  Tpeak–Tend interval as an index of transmural dispersion of repolarization , 2001, European journal of clinical investigation.

[18]  G. Talbot,et al.  Effect of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval). , 1999, Clinical therapeutics.

[19]  J. Barbey.  Drug-induced torsade de pointes: the perspectives of industry , 2001 .

[20]  I. Cavero.  Safety Pharmacology Society: 7th Annual Meeting , 2008 .

[21]  Guy Salama,et al.  Mouse models of long QT syndrome , 2007, The Journal of physiology.

[22]  W S Redfern,et al.  Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey. , 2001, Cardiovascular research.

[23]  J. Maylie,et al.  The novel class III antiarrhythmics NE-10064 and NE-10133 inhibit IsK channels expressed in Xenopus oocytes and IKs in guinea pig cardiac myocytes. , 1994, Biochemical and biophysical research communications.

[24]  W. Crumb,et al.  Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions. , 2000, The Journal of pharmacology and experimental therapeutics.

[25]  P. Hoffmann,et al.  Blinded Test in Isolated Female Rabbit Heart Reliably Identifies Action Potential Duration Prolongation and Proarrhythmic Drugs: Importance of Triangulation, Reverse Use Dependence, and Instability , 2003, Journal of cardiovascular pharmacology.

[26]  T. Iga,et al.  Sustained QT prolongation induced by tacrolimus in guinea pigs. , 1999, Life sciences.

[27]  Y. Mizuki,et al.  Effects of 5-HT(4) receptor agonists, cisapride and mosapride citrate on electrocardiogram in anaesthetized rats and guinea-pigs and conscious cats. , 2001, Acta Pharmacologica et Toxicologica.

[28]  John Webster,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics, 8th ed , 1992 .

[29]  G. Scholtysik,et al.  Generating and influencing Torsades de Pointes – like polymorphic ventricular tachycardia in isolated guinea pig hearts , 1998, Basic Research in Cardiology.

[30]  González Ma,et al.  Pharmacokinetic overview of oral second-generation H1 antihistamines. , 1998 .

[31]  Hiroyasu Miyazaki,et al.  QT PRODACT: in vivo QT assay in anesthetized dog for detecting the potential for QT interval prolongation by human pharmaceuticals. , 2005, Journal of pharmacological sciences.

[32]  Todd Wisialowski,et al.  Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. , 2004, European journal of pharmacology.

[33]  Xiaozhou Yao,et al.  Propranolol inhibits the human ether-a-go-go-related gene potassium channels. , 2005, European journal of pharmacology.

[34]  K. S. Estes,et al.  Pharmacokinetic overview of oral second-generation H1 antihistamines. , 1998, International journal of clinical pharmacology and therapeutics.

[35]  B. Fermini,et al.  The impact of drug-induced QT interval prolongation on drug discovery and development , 2003, Nature Reviews Drug Discovery.

[36]  Derek Leishman,et al.  Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. , 2002, Current opinion in drug discovery & development.

[37]  J. Levron,et al.  The Pharmacokinetics of Droperidol in Anesthetized Patients , 1986, Anesthesiology.

[38]  R. Shah,et al.  Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. , 2005, Heart rhythm.

[39]  H. R. Lu,et al.  Inhibition of Na+/Ca2+ overload with R 56,865 protects against cardiac arrhythmias elicited by ouabain in vivo in guinea-pigs. , 1993, European journal of pharmacology.

[40]  C. L. Ferguson,et al.  Torsades de pointes occurring in association with terfenadine use. , 1990, JAMA.

[41]  J. Miceli,et al.  The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers. , 2000, British journal of clinical pharmacology.

[42]  R. Hamlin,et al.  QT and RR intervals in conscious and anesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[43]  Serge Richard,et al.  Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres , 2005, British journal of pharmacology.

[44]  G. Tomaselli,et al.  Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices. , 2005, Journal of pharmacological and toxicological methods.

[45]  R. Sansone,et al.  QTc Prolongation Due to Propranolol Overdose , 2003, International journal of psychiatry in medicine.